Product Description
Ticagrelor (Brilique™, Brilinta®), a cyclopentyl-triazolopyrimidine, is an orally active, reversible, and selective adenosine diphosphate (ADP) receptor antagonist indicated for use in patients with acute coronary syndromes (ACS). Ticagrelor has a faster onset of action and provides greater inhibition of platelet aggregation than clopidogrel. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25672642/)
Mechanisms of Action: P2Y12 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Ischemic Stroke|Myocardial Infarction|Pneumonia|Thrombosis
Phase 1: Acute Coronary Syndrome|Coronary Thrombosis|Healthy Volunteers|Insomnia|Oncology Solid Tumor Unspecified|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-507015-35-00 | P3 |
Unknown Status |
Coronary Artery Disease |
2031-02-28 |
|
| ANGIODAPT | P3 |
Active, not recruiting |
Coronary Artery Disease |
2029-07-21 |
|
| PATH STROKE C | P3 |
Not yet recruiting |
Ischemic Stroke |
2027-06-30 |
|
| REMAP-CAP | P3 |
Recruiting |
Influenza, Human|Pneumonia|COVID-19 |
2026-02-01 |